ANGO logo

ANGO
Angiodynamic Inc

1,036
Loading...
Loading...
News
all
press releases
AngioDynamics NanoKnife System Named to TIMEs 2025 Best Inventions List
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient...
Business Wire·7d ago
News Placeholder
More News
News Placeholder
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
Zacks·17d ago
News Placeholder
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +28.57% and +4.75%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
Zacks·28d ago
News Placeholder
Nutriband Inc. (NTRB) Reports Q2 Loss, Lags Revenue Estimates
Nutriband (NTRB) delivered earnings and revenue surprises of -1,147.06% and -11.77%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Why Is Penumbra (PEN) Up 5% Since Last Earnings Report?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago
News Placeholder
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones, and a balanced portfolio despite tariff headwinds.
Zacks·2mo ago
News Placeholder
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.
Zacks·3mo ago
News Placeholder
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +76.92% and +7.52%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System
Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.
Zacks·4mo ago

Latest ANGO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.